Clinical Trials · NCT02492763
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 176
- Start date
- Jul 2015
- Locations
- See registry
- Primary endpoint
- Change From Baseline in Hemoglobin A1C (A1C) at Week 12